| Name | Title | Contact Details |
|---|
Launched in 2022 and started from the seeds of LFA Machines and Vivion Inc., Operio Group was conceived from a simple idea: customers do not need machines or ingredients, they need solutions to make products. Operio Group has been set up to invest in companies that directly serve the food, beverage, nutraceutical and pharmaceutical manufacturing industries. Aiming to bring together multidisciplinary teams from different sections of the supply chain in the industries that it serves, Operio Group is able to not just provide products but support people through the consolidated knowledge of their brands.
AlterG is a company researching pressure-unweighting technology in producing Anti-Gravity Treadmill™ for physical therapy and training.
The Y: Were for youth development, healthy living, and social responsibility
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.
Pharos Innovations is a Northfield, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.